Part of a two-case challenge series focused on the US healthcare system, this interactive module applies your PET imaging expertise to real-world Alzheimer’s disease decision-making. Work through scenarios involving early cognitive concerns, risk factors, and biomarker-guided treatment questions. Practice translating imaging evidence into clear clinical communication.
If you have any questions or comments on the topics discussed, please share these through our Imaging Exchange.
Title: Case Challenge USA: Biomarkers and Imaging-Guided Treatment Decisions
Release date: February 6, 2026
Estimated time to complete activity: 10-15 mins
This program is intended for Imaging physicians, including Nuclear Medicine Physicians, Radiologists, Neuroradiologists, Radiology Physician Assistants, Imaging Residents. It is also suitable for Neurologists.
Following completion of this independent educational program, you will be able to:
Prof Jonathan E. McConathy
Professor and Director, Division of Molecular Imaging and Therapeutics
University of Alabama, Birmingham, USA
Disclosures
Honoraria from Novartis, Telix, Eli Lilly/Avid; Consulting fees from GE Healthcare, Novartis; and research support from Eli Lilly/Avid, GE Healthcare.
Other financial or material support
Clinical trial sponsors: Cytosite Biopharma, RayzeBio, Novartis, Telix, Fusion Pharmaceuticals, Clarity Pharmaceuticals
